Tamoxifen-Induced Non-alcoholic Steatohepatitis Cirrhosis.
- Author:
Tae Hwan KIM
1
;
Young Bae KIM
;
Jae Youn CHEONG
;
Sung Won CHO
;
Soon Sun KIM
Author Information
1. Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea. cocorico99@gmail.com
- Publication Type:Case Report
- Keywords:
Breast neoplasms;
Chronic hepatitis B;
Non-alcoholic fatty liver disease;
Liver cirrhosis;
Tamoxifen
- MeSH:
Adult;
Breast;
Breast Neoplasms;
Carcinoma, Ductal;
Diabetes Mellitus, Type 2;
Diagnosis;
Fatty Liver*;
Female;
Fibrosis*;
Hepatitis B, Chronic;
Humans;
Hypertension;
Korea;
Liver Cirrhosis;
Non-alcoholic Fatty Liver Disease;
Tamoxifen;
Ultrasonography
- From:Soonchunhyang Medical Science
2018;24(1):81-84
- CountryRepublic of Korea
- Language:English
-
Abstract:
Non-alcoholic fatty liver disease has been observed in over 30% of patients who have received tamoxifen therapy. However, tamoxifen-induced non-alcoholic steatohepatitis (NASH) cirrhosis has never been reported in Korea. A 41-year-old woman was diagnosed with invasive ductal carcinoma in the left breast. She had well-controlled type 2 diabetes mellitus, hypertension, and chronic hepatitis B. Ultrasonography showed mild fatty liver. Chronic hepatitis B had been treated with clevudine one month before the diagnosis of breast cancer. The patient was diagnosed with NASH cirrhosis 39 months after tamoxifen treatment. Careful observation for the development of NASH cirrhosis is warranted during tamoxifen therapy.
